Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
2017 · ESMO Open · 71 citations
https://doi.org/10.1136/esmoopen-2017-000168
A
Amit Joshi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
403
Papers
5.0K
Citations
33
h-index
105
i10-index
Amit Joshi is an academic researcher from Kumaun University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Head and Neck Cancer Studies & Lung Cancer Research Studies. The author has an h-index of 33, co-authored 343 publications.
ORCID: 0000-0003-4561-6135Papers by this author
worksPhase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
2019 · EClinicalMedicine · 9 citations
https://doi.org/10.1016/j.eclinm.2019.03.011
Cabozantinib: A narrative drug review
2023 · Cancer Research Statistics and Treatment · 9 citations
https://doi.org/10.4103/crst.crst_9_23
Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer
2024 · Cancer Chemotherapy and Pharmacology · 9 citations
https://doi.org/10.1007/s00280-024-04697-x
Primary mediastinal germ cell tumours with high prevalence of somatic malignancy: An experience from a single tertiary care oncology centre
2021 · Annals of Diagnostic Pathology · 7 citations
https://doi.org/10.1016/j.anndiagpath.2021.151763
Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India✰
2020 · Cancer Treatment and Research Communications · 6 citations
https://doi.org/10.1016/j.ctarc.2020.100269
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat